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Abstract
Background: Alzheimer’s disease (AD) is characterized by extracellular β-amyloid (Aβ) plaques, neurofibrillary
tangles (NFTs), and microglia-dominated neuroinflammation. The Nogo/NgR signal pathway is involved in AD
pathological features, but the detailed mechanism needs further investigation. Our previous studies have confirmed
that the activation of NgR on microglia by Nogo promotes the expression of proinflammatory cytokines and
inhibits cell adhesion and migration behaviors. In the present study, we investigated the effects of Nogo/NgR
signaling pathway on the pathological features of AD and possible mechanisms.
Methods: After NEP1-40 (a competitive antagonist of Nogo/NgR pathway) was intracerebroventricularly
administered via mini-osmotic pumps for 2 months in amyloid precursor protein (APP)/PS1 transgenic mice, plaque
load, tau phosphorylation, and inflammatory responses were determined. After primary mouse neurons were
exposed to the conditioned medium from BV-2 microglia stimulated by Nogo, the production of Aβ and
phosphorylation of tau was quantified by ELISA and western blot.
Results: Inhibition of the Nogo/NgR signaling pathway ameliorated pathological features including amyloid
plaques and phosphorylated levels of tau in APP/PS1 mice. In addition, after treatment with the conditioned
medium from BV-2 microglia stimulated by Nogo, Aβ production and tau phosphorylation in cultured neurons
were increased. The conditioned medium also increased the expression of APP, its amyloidogenic processing, and
the activity of GSK3β in neurons. The conditioned medium was also proinflammatory medium, and the blockage of
the Nogo/NgR pathway improved the neuroinflammatory environment in APP/PS1 mice.
Conclusions: Taken together, the neuroinflammation mediated by Nogo/NgR pathway in microglia could directly
take part in the pathological process of AD by influencing the amyloidogenesis and tau phosphorylation. These
results contribute to a better understanding of AD pathogenesis and could offer a new therapeutic option for
delaying the progression of AD.
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Background
Alzheimer’s disease (AD) is the most frequent cause of
dementia [1]. More than 24 million people are affected
in the world [2]. The two core pathological hallmarks of
AD are β-amyloid (Aβ) plaques and neurofibrillary tan-
gles (NFTs).
Nogo-A is a myelin-associated inhibitory molecule
that inhibits the growth of neurite and reconnection in
CNS diseases through cellar and molecular events [3, 4].
Nogo receptor (NgR) is a glycosylphosphatidylinositol-
linked receptor, which binds with high affinity to Nogo-
66, a hydrophilic 66 amino acid-long region of Nogo-A
[5]. Recently, a number of studies have suggested that
Nogo and its receptor participate in the AD pathogen-
esis. For example, it has been demonstrated that the ex-
pression of Nogo-A is increased in the hippocampus of
patients with AD and is also localized in senile plaques
around amyloid deposits [6]. Nogo-A shifts to the neur-
onal perikarya in human AD brain and amyloid precur-
sor protein (APP)/PS1 transgenic mice [7]. Moreover,
deleting Nogo ameliorates learning and memory deficits
of APP transgenic mice [8]. Furthermore, the expression
of NgR and downstream signaling molecules are in-
creased in patients with AD and aged rats with deficits
of spatial cognition [9, 10], and NgR also diffuses around
amyloid plaques [7]. Recently, a study has shown that
neuronal overexpression of NgR impairs cognitive func-
tion in AD transgenic mice [11]. Intracerebroventricular
and subcutaneous injection of NgR(310)ecto-Fc reduce
Aβ plaque load in the brain [7, 12] and subcutaneous in-
fusion improves spatial memory in APPswe/PSEN-1ΔE9
transgenic mice [12]. Thus, despite several studies that
imply the relationship between the Nogo, NgR, and AD,
only a few detailed mechanisms have been provided to
date.
Neuroinflammation has been recognized as an import-
ant cause of the AD and parallels disease severity [13, 14].
Many researchers have found that microglia, primary
immune cells of the brain, play a central role in the
pathogenesis of AD. Microglia are key innate immune
cells that mediate inflammatory process in the AD
brain [15]. In AD mouse models and patients, microglia
are activated and recruited to Aβ deposits [16, 17]. Our
previous research has confirmed that NgR is also
expressed on microglia and the binding of Nogo with
NgR could inhibit the microglia adhesion and migration
through RhoA pathway in vitro [18]. The interaction of
Nogo peptide with NgR expressed on microglia elevates
the expression of proinflammatory enzymes and cyto-
kines in vitro, which is mediated by the nuclear factor-
kappa B (NF-κB) and signal transducers and activators
of transcription3 (STAT3) pathways [19]. These find-
ings initiate an interesting speculation about whether
neuroinflammatory environment produced by Nogo-
stimulated microglia play a role in the pathogenesis of
AD. In this study, we explored whether the Nogo/NgR
signaling pathway in the microglia participate in the
AD pathogenesis. The results showed that the blockage
of Nogo/NgR signaling pathway ameliorated AD patho-
logical features including Aβ deposition and tau hyper-
phosphorylation in APP/PS1 mice. Moreover, their
mechanism may be related to the neuroinflammatory




C57BL/6J mice were obtained from Zhejiang Laboratory
Animal Center (Hangzhou). APP/PS1 transgenic mice
were purchased from the animal model center of Nan-
jing University (Nanjing, China); the mice were gener-
ated from the B6C3-Tg (APPswe, PSEN1dE9) 85Dbo/J
double transgenic mouse line (Stock # 004462) provided
by the National Jackson Animal Center (Bar Harbor,
Maine, USA). All of the mice were raised in a thermo-
static 12-h/12-h dark-light cycle environment, with free
access to food and water. All animal tests were carried
out in accordance with the US National Institute of
Health (NIH) Guide for the Care and Use of Laboratory.
All experimental procedures were approved by Institu-
tional Animal Care and Use Committee (IACUC) of the
Nanjing Medical University Experimental Animal
Department.
NEP1-40 treatment
To administer NEP1-40 peptide to mice, APP/PS1 mice
at 6 months were anesthetized using chloral hydrate
(100 mg/kg, i.p.), and a burr hole was drilled on the
skull. A cannula (Alzet brain infusion kit II; Alza, Palo
Alto, CA) was stereotactically introduced into the right
lateral ventricle at the coordinates: 0.6 mm posterior
and 1.2 mm lateral to the bregma and 2.0 mm deep to
the pial surface. The cannula was held in place with
cyanoacrylate, and the catheter was attached to osmotic
micropump (Alzet 2004, 0.25 μl/h for 28 d; Alza). The
pump was placed subcutaneously in the midscapular
area of the back of the mice. Animals were catego-
rized into vehicle (97.5 % PBS + 2.5 % DMSO)-treated
and NEP1-40 (500 μM in vehicle)-treated groups.
Pumps were replaced after 28 days and connected to
the same cannula.
Tissue preparation
After infusion for 2 months, mice were deeply anesthe-
tized using chloral hydrate (100 mg/kg, i.p.) and
perfused intracardially with cold 4 % paraformaldehyde
(PFA) in PBS followed by perfusion with PBS. Brain
tissues were fixed with PFA overnight at 4 °C and
Fang et al. Journal of Neuroinflammation  (2016) 13:56 Page 2 of 17
equilibrated by immersing in 15 and 30 % sucrose in
PBS overnight at 4 °C, respectively. The brain tissues
were then sectioned to a thickness of 15 μm on a Leica-
1900 cryostat (Leica Instruments, Germany). The sec-
tions were used for immunohistochemistry or thioflavin
S staining and stored at −80 °C.
Immunohistochemistry
Immunohistochemistry was performed as described earl-
ier with some modifications [20]. Briefly, the brain sec-
tions were degreased in acetone for 20 min at 4 °C.
Then, the sections were incubated with primary anti-
bodies overnight at 4 °C after incubation with a blocking
solution (10 % normal goat serum, 0.3 % Triton X-100
in PBS) at room temperature for 1 h. The following pri-
mary antibodies were used: rabbit anti-Nogo-A poly-
clonal antibody (1:50; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse anti-6E10 monoclonal antibody
(1:500; Covance, Princeton, NJ), and rabbit anti-Iba-1
polyclonal antibody (1:200; Wako Chemicals, Japan).
After rinsing in PBS, the sections were incubated with
secondary antibodies: Alexa Fluo-488 conjugated goat
anti-rabbit IgG antibody (1:300; Invitrogen), Alexa Fluo-
594 conjugated goat anti-mouse IgG antibody (1:500;
Invitrogen), and Hoechst 33342 to counterstain nuclei
when necessary.
In thioflavin S (ThioS, Sigma) staining [21], the brain
sections were incubated with a 1 % ThioS solution dis-
solved in distilled water containing 50 % ethanol for
5 min and differentiated in 50 % ethanol thrice. The
fluorescent imaging was visualized by using Olympus
IX-81 inverted fluorescence microscope and FV1000
confocal laser scanning microscope (Olympus Corpor-
ation, Japan). For quantification of amyloid load, the area
of the five sections of the cortex and hippocampus in
each group was calculated and analyzed using the
Image-Pro Plus software.
ELISA
For Aβ ELISA assay, the brain was homogenized as de-
scribed previously [22]. Briefly, cortical and hippocampal
tissues were homogenized in TBS containing a protease
inhibitor cocktail (Roche) and then centrifuged at
16,000g for 30 min at 4 °C. The supernatant (TBS-sol-
uble fraction) was collected and stored at −80 °C. The
pellets were homogenized in TBS plus 1 % Triton X-100
(TBS-T) containing a protease inhibitor cocktail (Roche),
sonicated for 5 min at 4 °C in a water bath, and centri-
fuged at 16,000g for another 30 min at 4 °C. The super-
natant (TBS-T-soluble fraction) was collected and stored
at −80 °C. The pellets were extracted for a third time
with an ice-cold guanidine buffer (5 M guanidine HCl/
50 mM Tris, pH 8.0) and in hence referred to as the
guanidine-soluble fraction. The protein concentration of
all samples was measured using a bicinchoninic acid
protein assay kit (Beyotime Biotechnology). The concen-
trations of Aβ in three separate fractions of brain sam-
ples were determined using Aβ42 and Aβ40 ELISA kits
(Invitrogen) following the manufacturer’s instructions.
Brain tissues were homogenized in cell lysate buffer
(RayBiotech. Inc., San Diego, CA) supplemented with a
protease inhibitor cocktail (Roche) and centrifuged at
12,000g for 20 min at 4 °C. The supernatant was col-
lected and stored at −80 °C. The protein concentration
was measured using a bicinchoninic acid protein assay
kit (Beyotime Biotechnology). The proportions of
interleukin-1β (IL-1β) and interleukin-4 (IL-4) were ex-
amined using IL-1β and IL-4 ELISA kits (RayBiotech.
Inc.) following the manufacturer’s instructions.
Western blot analysis
After 2 months of administration, mice were deeply
anesthetized with chloral hydrate (100 mg/kg, i.p.).
After perfusion with PBS, the brain was quickly dis-
sected and stored at −80 °C until further use. Snap-
frozen brain tissue was homogenized in RIPA buffer
(Beyotime Biotechnology) supplemented with a prote-
ase inhibitor cocktail (Roche). Extracts were centrifuged at
12,000g for 20 min at 4 °C, and the supernatant was col-
lected and the protein concentration was determined
using a bicinchoninic acid protein assay kit (Beyotime
Biotechnology).
Neurons obtained from different treatments were lysed
in RIPA buffer (Beyotime Biotechnology) containing a
protease inhibitor cocktail (Roche). The cell extracts
were centrifuged at 12,000g at 4 °C for 20 min to remove
cell debris. The supernatant was collected and the pro-
tein concentration was determined using a bicinchoninic
acid protein assay kit (Beyotime Biotechnology, China).
Supernatant protein (50 μg) was electrophoretically
separated using denaturing gels and transferred onto
nitrocellulose membranes. Membranes were blocked for
1 h at room temperature with 5 % bovine serum albu-
min in Tris-buffered saline Tween-20 and then
incubated overnight at 4 °C with specific primary anti-
body. The following antibodies were used: mouse anti-
APP polyclonal antibody (1:500; Sigma), mouse anti-
Presenilin-1 polyclonal antibody (1:500; Millipore),
rabbit anti-BACE1 polyclonal antibody (1:800; Milli-
pore), mouse anti-β-CTF polyclonal antibody (1:1000,
Sigma), rabbit anti-a disintegrin and metalloproteinases
10 (ADAM10) polyclonal antibody (1:800; Millipore),
rabbit anti-tau-1 polyclonal antibody (1:500; Millipore),
rabbit anti-p-tau at Thr202/205 polyclonal antibody
(1:500; Santa Cruz Biotechnology), rabbit anti-p-tau at
Ser396 polyclonal antibody (paired helical filament
(PHF) 13, 1:1000; Cell Signaling Technology Inc., Bever-
ley, MA, USA), rabbit anti-GSK-3β polyclonal antibody
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(1:1000; Cell Signaling Technology Inc.), rabbit anti-p-
GSK3β at pY216 polyclonal antibody (1:1000; Abcam,
Cambridge, MA, USA), rabbit anti-inducible nitric oxide
synthase (iNOS) polyclonal antibody (1:800; Abcam),
goat anti-cyclooxygenase-2 (COX-2) polyclonal antibody
(1:500; Santa Cruz Biotechnology Inc.), and mouse anti-
β-actin monoclonal antibody (1:2000; Santa Cruz Bio-
technology). After immunoblotting with horseradish
peroxidase-conjugated secondary antibodies goat anti-
mouse IgG (1:10000; Sigma), rabbit anti-goat IgG (1:500;
R&D System, Minneapolis, MN, USA), or goat anti-
rabbit IgG (1:5000; Cell Signaling Technology Inc.) con-
jugated with horseradish peroxidase, immunoreactive
bands were detected by chemiluminescence reagents
(ECL; Millipore).
The images of protein bands were captured with a
Bio-Rad Gel Doc XR documentation system for blot
densitometry assay. The relative expressions of the pro-
tein were determined by scanning the pixel density of re-
sultant blots using Quantity One software.
Quantitative real-time PCR (RT-PCR)
For RT-PCR, total RNA was extracted from the brain
tissue or BV-2 microglia cells in TRIzol on ice (Vazyme,
NJ, China). HiScript First Strand cDNA Synthesis Kit
(Vazyme) was used to convert RNA to cDNA. To quan-
tify RNA, real-time PCR was performed using AceQTM
qPCR SYBR Green Master Mix (Vazyme) on a LightCy-
cler96 PCR system (Roche). The cycle time values of
each sample were normalized to GAPDH.
The following PCR primer sequences were used for de-
tecting transcriptions: GAPDH F: 5′-GGTGAAGGTCGG
TGTGAACG-3′, R: 5′-CTCGCTCCTGGAAGATGGTG-
3′; iNOS F: 5′-ACCTTGTTCAGCTACGCCTT-3′, R: 5′-
CATTCCCAAATGTGCTTGTC-3′; IL-1β F: 5′-TCAGG-
CAGGCAGTATCACTC-3′, R: 5′-CATGAGTCACAGAG
GATGGG-3′; tumor necrosis factor-α (TNF-α) F: 5′-TC
TCTTCAAGGGACAAGGCT-3′, R: 5′-GGCAGAGAGG
AGGTTGACTT-3′; IL-6 F: 5′-ACTTCACAAGTCGGA
GGCTT-3′, R: 5′-TTGCCATTGCACAACTCTTT-3′; CO
X-2 F: 5′-ATGAGCACAGGATTTGACCA-3′, R: 5′-TG
GGCTTCAGCAGTAATTTG-3′; chemokine (C-C motif)
ligand 2 (CCL2) F: 5′-GCATCTGCCCTAAGGTCTTC-3′,
R: 5′-AAGTGCTTGAGGTGGTTGTG-3′; arginase 1 (Arg
1) F: 5′-CAGTGGCTTTAACCTTGGCT-3′, R: 5′-GTCA
GTCCCTGGCTTATGGT-3′; found in inflammatory zone
1 (Fizz1) F: 5′-CTGCTACTGGGTGTGCTTGT-3′, R: 5′-
GGCAGTTGCAAGTATCTCCA-3′; chitinase-like 3 (Chil
3, Ym1) F: 5′-TCTATGCCTTTGCTGGAATG-3′, R: 5′-
CAGGTCCAAACTTCCATCCT-3′; IL-4 F: 5′-TGTAC-
CAGGAGCCATATCCA-3′, R: 5′-TTCTTCGTTGCTGT
GAGGAC-3′; cd206 F: 5′-TGATTACGAGCAGTGGAAG
C-3′, R: 5′- GTTCACCGTAAGCCCAATTT-3′; interleu
kin-10 (IL-10) F: 5′-CAGAGCCACATGCTCCTAGA-3′,
R: 5′-GGCAACCCAAGTAACCCTTA-3′. The primers were
synthesized by Nanjing Genscript (Nanjing, China).
Cell cultures and treatments
BV-2 murine microglia cell was routinely grown in Dul-
becco’s modified Eagle’s medium (DMEM, Gibco, Carls-
bad, CA, USA) supplemented with 10 % fetal bovine
serum (FBS, Gibco), penicillin (0.1 %), and streptomycin
(0.1 %) at 5 % CO2, 37 °C.
BV-2 microglia cells were treated according to the
method described with modifications [23]. Briefly, 96-
well plates (Corning, New York, USA) were coated
with methanol-solubilized nitrocellulose and washed
with ddH2O. Then, the wells were incubated with
poly-L-lysine (PLL, 0.05 mg/ml, Sigma, St Louis, MO,
USA) for 2 h at 37 °C and washed with ddH2O.
Later, Nogo-P4 (Alpha Diagnostic International Inc.,
San Antonio, TX) was applied at 100 μg/mL and
coated overnight at 4 °C. Nogo-P4 is a 25 aa inhibi-
tory peptide sequence (residues 31–55 of Nogo-66), a
potent inhibitory component of Nogo-A [3]. After
transfection, BV-2 microglia cells were added onto
the wells pre-coated with Nogo-P4 or PBS at a dens-
ity of 5 × 105 cells/mL and cultured for 6 h. Then,
conditioned medium was collected and centrifuged to
discard cell debris for further experiment.
Primary cortical neuron cultures were prepared fol-
lowing the described method with some modifications
[24]. Briefly, cortices of C57BL/6J mouse at embryonic
15–17 days were removed, dissected free of meninges,
and dissociated in 0.125 % trypsin. Then, dissociated
cells were plated in PLL (0.05 mg/ml, Sigma)-coated 24-
or 96-well plates at a density of 3 × 105 cells/mL in
DMEM supplemented with 10 % FBS and cultured at
37 °C in 5 % CO2. After 4 h, the medium was replaced
with neurobasal medium (Gibco) supplemented with
B27 supplements (Gibco). About 95 % of these cells
were positive for microtubule-associated protein 2
(MAP2), a marker for neurons. After 6 days of in vitro
culture, the medium was replaced with BV-2 microglia-
conditioned medium for a further 24 h.
Transfection
According to the gene sequence of mouse NgR, a small
interfering RNA (siRNA) targeting NgR (NgR siRNA,
sense: 5′-UUCUCCGAACGUGUCACGUTT-3′ and anti-
sense: 5′-ACGUGACACGUUCGGAGAATT-3′) was designed.
Non-specific sequences (control siRNA, sense: 5′-GCCGAAAU-
CUCACUAUCCUTT-3′ and antisense: 5′-AGGAUAGUGA-
GAUUUCGGCTT-3′) were used as a control. The siRNA was
synthesized by Shanghai GenePharma Co. Ltd. (Shanghai,
China).
BV-2 microglia cells were seeded onto 24-well plates
at the density of 1 × 105 cells/well and cultured
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overnight. Before transfection, the medium was changed
to a medium containing no serum for 2 h. Lipofecta-
mine® 2000 Transfection Reagent (Invitrogen, Carlsbad,
CA, USA) was used to transfect the siRNAs. Treatment
with control siRNA or NgR siRNA was realized at a final
dose of 60 nM siRNA/well and replaced to a fresh
medium after 5 h. These cells were subsequently cul-
tured for 31 h.
Quantification of Aβ40 and Aβ42 levels
Primary cortical neurons were treated with BV-2
microglia-conditioned medium for 24 h, and the se-
cretion and production of Aβ were detected as de-
scribed previously [25, 26]. The medium of neurons
was then collected and centrifuged for 20 min at
12,000g to remove cell debris, and then, the levels of
secreted Aβ40 and Aβ42 were measured using mouse
Aβ40 ELISA kits (Invitrogen) and mouse Aβ42 ELISA
kits (Invitrogen) following the manufacturer’s instruc-
tions. To determine the production of intracellular
Aβ, the treated cells were lysed with cold radio im-
mune precipitation assay buffer (Roche) containing a
protease inhibitor cocktail (Roche) and centrifuged at
12,000g for 20 min to remove cell debris. The pro-
portions of Aβ40 and Aβ42 in protein extracts were
measured using mouse Aβ40 ELISA kits (Invitrogen)
and mouse Aβ42 ELISA kits (Invitrogen) according to
the manufacturer’s instructions. The levels of Aβ were
normalized to the amount of total protein in neurons.
Measurement of secretase activity
Primary cortical neurons were harvested, and the ac-
tivity of secretases was measured, as described previ-
ously with some modifications [27]. Briefly, the cells
were lysed in extraction buffer on ice for 10 min,
centrifuged at 10,000g at 4 °C for 5 min, and the pro-
tein concentration was quantified. β-secretase activity
was measured using β-secretase activity kit (Biovision,
Milpitas, CA, USA) according to the manufacturer’s
instructions. Fluorescence was measured with an
emission and excitation wavelength of 495–510 and
335–355 nm, respectively, using a Safire2 microplate
reader (TECAN, Salzburg, Austria). The activity of α-
secretase was measured using the fluorogenic α-
secretase substrate II with EDANS/DABCYL (480 nm
emission and 330 nm excitation, Millipore), and γ-
secretase activity was measured using a fluorogenic γ-
secretase substrate with NMA/DNP (435 nm emission
and 330 nm excitation, Millipore) 12 h after incuba-
tion in the same lysate.
Thioflavin-T (ThT) binding assay
After stimulated by PBS or Nogo-P4, the effects of BV-2
microglia-conditioned medium on Aβ aggregation and
fibrillar Aβ depolymerization were examined using ThT
(Sigma) binding assay [28, 29]. Specifically, Aβ1−42 (Ana-
Spec Inc., San Jose, CA) was prepared as a 1-mg/mL
stock solution in DMSO (Sigma). ThT solution was pre-
pared as a 1-mg/mL stock solution in ddH2O and used
at a final concentration of 5 mM in PBS (pH 7.4). Aβ1–
42 monomers were prepared at the final desired concen-
tration (10 μM) in PBS (pH 7.4) and were added to the
appropriate wells of a 96-well black plate (10 μl/well).
An equal volume of the conditioned medium or PBS so-
lution was added to the Aβ1–42-containing wells. Plates
were then placed in 37 °C. After 24 h, 180-μl ThT solu-
tion was added to the wells. Following 1-min incubation
at room temperature, Aβ peptide aggregation was
measured (Safire2 microplate reader, TECAN) as the in-
crease in relative ThT fluorescence (excitation at
450 nm, emission at 480 nm). To test the effects of the
conditioned medium on fibrillar Aβ1–42 depolymerization,
20-μl Aβ1–42 monomers (20 μM) were added to a 96-well
black plate. After incubation for 24 h at 37 °C, an equal
volume of the conditioned medium or PBS solution was
added to the Aβ1–42-containing wells and 160-μl ThT so-
lution was added to each well. Following 1-min incubation
at room temperature, ThT fluorescence was measured. Ef-
fects of microglia-conditioned medium on Aβ1–42 aggre-
gation and depolymerization were represented as relative
changes in ThT fluorescence as compared to fluorescence
of the Aβ1–42 solution.
Statistical analysis
All presented data represent the results of three inde-
pendent experiments. Statistical analysis was performed
using Student’s t test or one-way analysis of variance
(ANOVA) with post hoc Tukey’s test using Graph Pad
Prism 5 software (Graph Pad Software Inc., La Jolla, CA,
USA). All data were presented as mean ± SD. p value of
*p < 0.05 was considered statistically significant.
Results
Inhibition of the Nogo/NgR pathway reduced Aβ plaque
deposition in APP/PS1 mice
To investigate the effects of Nogo/NgR pathway on
pathological features of AD, NEP1-40 was intracerebro-
ventricularly administered by continuous infusion into
APP/PS1 mice aged from 6 to 8 months old with an
Alzet mini-pump. APP/PS1 transgenic mice is a com-
monly used AD animal model [30, 31]. NEP1-40 is a
competitive antagonist peptide of Nogo/NgR pathway
derived from the first 40 amino acids of the Nogo-66,
prevents the combination of Nogo with NgR, and en-
ables the promotion of the axonal outgrowth through
blocking the binding of Nogo to NgR in vitro and in vivo
[32–35].
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After 2 months, mice were killed, and in order to de-
termine the deposition of Aβ plaque in APP/PS1 mice,
the brain sections were stained for fibrillar Aβ with
ThioS or 6E10 (Aβ antibody). Quantitative analysis in
the hippocampal and cortical regions revealed significant
reduction in the deposition of Aβ plaque in APP/PS1
mice after NEP1-40 treatment as compared with the ve-
hicle group (Fig. 1a–d). To further validate the immuno-
histochemical results, the levels of different Aβ isoforms
by performing ELISA of cortical and hippocampal ho-
mogenates derived from the vehicle- or NEP1-40-
infused APP/PS1 mice were measured. As shown in
Fig. 1e–h, NEP1-40 administration significantly de-
creased the concentrations of Aβ42 and Aβ40 in TBS-
soluble fractions, TBS-T-soluble fractions, and guanidine
chloride-soluble fractions, which were enriched in
monomeric, oligomer, and high molecular weight aggre-
gated Aβ species in the cortex and hippocampus. These
Fig. 1 Inhibition of the Nogo/NgR pathway reduced Aβ plaque deposition in APP/PS1 mice. a, b Mice brain sections from APP/PS1 mice were stained
with thioflavin S and calculated as Aβ-positive area fraction in the hippocampal and cortical regions at 8 months of age. Bar = 100 μM. Values were
reported as mean ± SD, as a percentage of values determined in the vehicle group (control, 100 %). The Aβ plaque in the brain was estimated after
immunohistochemistry with Aβ antibody (6E10), and the position area fraction of the hippocampal and cortical regions of brain tissues were calculated
(c, d). Bar = 100 μM. Values were reported as mean ± SD, as a percentage of values determined in the vehicle group (control, 100 %). e–h The cortex
or hippocampus of APP/PS1 mice was homogenized and separated into TBS-, TBST-, and guanidine-soluble fractions. The proportions of Aβ42 (e, f)
and Aβ40 (g, h) were measured using ELISA. e, g The cortex of APP/PS1 mice; f, h The hippocampus of APP/PS1 mice. Values were reported as mean
± SD. *p < 0.05; **p < 0.01; ***p < 0.001, when compared with the vehicle group, n = 3–6
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results imply that inhibition of Nogo/NgR pathway could
attenuate amyloid plaque deposition in AD animal
model.
Blockage of the Nogo/NgR pathway attenuated
amyloidogenic and induced non-amyloidogenic process-
ing of APP in APP/PS1 mice
Aβ is a cleavage product of APP. APP protein can be
processed by α-secretase in a non-amyloidogenic
pathway and also can be processed by β- and γ-
secretases in an amyloidogenic pathway which pro-
duces Aβ [36]. In order to study the expression and
processing of APP, the expression of APP and secre-
tases in APP/PS1 mice was examined using western
blot. Results in Fig. 2a, b showed that there was no
difference between the vehicle and the NEP1-40
group, indicating that basal level of APP expression
was unaltered after infusion of NEP1-40 in APP/PS1
mice. However, NEP1-40 treatment markedly reduced
BACE1 (Fig. 2c, d) and β-CTF (Fig. 2e, f ) levels, sug-
gesting that the expression and processing of β-
secretase were decreased by blocking the Nogo/NgR
pathway. Moreover, the expression of α-secretase
(ADAM10) was increased by NEP1-40 treatment in
APP/PS1 mice (Fig. 2g, h). Next, we noticed that the
expression of PS1 loop (a key component of γ-
secretase complex) was decreased in the NEP1-40
group compared with the vehicle group (Fig. 2i, j).
These data suggest that NEP1-40 treatment, blocking
the Nogo/NgR pathway, induced non-amyloidogenic
processing of APP and inhibited amyloidogenic pro-
cessing of APP. Hence, the observed reduction in
amyloid accumulation might be attributable to the
regulation of metabolic processing of APP.
Fig. 2 Blockage of Nogo/NgR pathway attenuated amyloidogenic and induced non-amyloidogenic processing of APP in APP/PS1 mice. Homogenates
from the brain tissue of 8-month-old APP/PS1 transgenic mice were subjected to western blot analysis with markers of APP expression and processing.
a, b APP. c, d BACE1. e, f β-CTF. g, h ADAM10. i, j PS1 loop. Values were reported as mean ± SD, as a percentage of values determined in the vehicle
group (control, 100 %). ***p < 0.001, when compared with the vehicle group, n = 3–6
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Decreasing of the phosphorylated levels of tau in APP/
PS1 mice after inhibition of the Nogo/NgR pathway
Another key pathological characteristic of AD is NFTs
which are composed predominantly of hyperphosphory-
lated tau protein and assembled primarily in the PHF con-
formation [37]. Thus, we next explored the effect of
inhibition of the Nogo/NgR pathway on the phosphoryl-
ation of tau using western blot. After NEP1-40 infusion,
the phosphorylated levels at Ser202/Thr205 of tau de-
tected by AT8 (Fig. 3a, b) and at Ser396 detected by
PHF13 were decreased in the APP/PS1 mice (Fig. 3c, d).
Anti-tau-1 antibody recognizes a non-phosphorylated tau
epitope, the higher expression of tau-1 reflected the reduc-
tion of phosphorylated levels of tau. Moreover, significant
reduction in phosphorylated GSK3β, an important tau
kinase [38], was found in NEP1-40-treated mice (Fig. 3e,
f ). These results indicate that the inhibition of the Nogo/
NgR pathway could alter tau phosphorylation through
inhibiting the activity of GSK3β and thus potentially affect
the accumulation of NFTs in the AD mice brain.
The conditioned medium (CM) from BV-2 microglia acti-
vated by the Nogo/NgR pathway increased the produc-
tion and the aggregation of Aβ in primary neurons
Above results showed that the Nogo/NgR signaling
pathway was involved in the development of AD patho-
logical features in APP/PS1 mice, but the mechanism
remained unclear. It has been reported that Nogo-A is
localized in senile plaques in patients with AD [6]. Con-
sistent with the results, we found that Nogo-A was co-
localized with Aβ plaques stained by 6E10 in APP/PS1
transgenic mice (Fig. 4a). Moreover, microglia was also
co-localized with Aβ plaques (Fig. 4b) and NgR was
expressed on the Iba+ microglia (Fig. 4c). Our previous
study found that Nogo/NgR signaling pathway is in-
volved in neuroinflammation through increasing the ex-
pression of inflammatory mediators in microglia in vitro
[19]. Hence, these data suggest that neuroinflammatory
environment induced by the Nogo/NgR pathway might
increase the production and the aggregation of Aβ in
primary neurons.
Fig. 3 Decreasing the phosphorylated levels of tau in APP/PS1 mice after inhibition of the Nogo/NgR pathway. The phosphorylation of tau (a–d)
and activation of GSK-3β (e, f) in the brain homogenates was quantified with western blot. a, b AT-8. c, d PHF13. Values were reported as mean
± SD. *p < 0.05; **p < 0.01, when compared with the vehicle group, n = 3–6
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To investigate the hypothesis, NgR in BV-2 microglia
was silenced by siRNA interference and then primary neu-
rons were exposed to the CM prepared from Nogo-P4
stimulated BV-2 microglia for 24 h. The expression of
NgR in BV-2 microglia was significantly decreased by NgR
siRNA interference (Additional file 1: Figure S1A, B), and
the cellular ability was not affected (Additional file 1: Figure
S1C). The levels of Aβ40 (Fig. 5a) and Aβ42 (Fig. 5b) in cell
lysates and in the medium (Aβ40, Fig. 5c; Aβ42, Fig. 5d) in
neurons exposed to the CM were significantly increased
compared with neurons exposed to the control PBS
medium. Compared with control siRNA-treated CM, NgR
siRNA treatment significantly attenuated the production of
Aβ40 (Fig. 5a) and Aβ42 (Fig. 5b) in cell lysates and in the
medium (Aβ40, Fig. 5c; Aβ42, Fig. 5d) when neurons were
induced by Nogo-P4. The background secretion of Aβ in
CM was eliminated (Additional file 2: Figure S2). Further-
more, the effects of the CM on the aggregation and
depolymerization of Aβ1–42 was investigated. Results in
Fig. 5e, f showed that the CM promoted the aggregation of
Aβ1–42 and inhibited depolymerization of Aβ1–42, which
was reversed by the treatment with NgR siRNA. Results
above indicated that the CM generated from Nogo/NgR-
activated BV-2 microglia promoted the production and re-
lease of Aβ in neurons and affected the aggregation and
depolymerization of Aβ1–42.
The CM derived from Nogo/NgR-activated BV-2 microglia
increased the APP expression and accelerated the amyloi-
dogenic processing of APP in primary neurons
The effects of the CM derived from Nogo/NgR-activated
BV-2 microglia on the expression and the processing of
APP were determined using western blot. As shown in
Fig. 6a, b, after neurons were stimulated by CM derived
from Nogo-P4-activated BV-2 microglia, the expression
of APP was increased in neurons and NgR siRNA inhib-
ited the effect of Nogo-P4. Moreover, it was measured
whether the processing of APP was affected by the CM.
When neurons were treated with the CM, a significant
increase in the expression of BACE1 and activity of β-
secretase in neurons was observed (Fig. 6a, c, d). The ex-
pression of ADAM10 and activity of α-secretase were
significantly decreased in neurons treated with the CM
(Fig. 6e–g). Although the expression of PS1 loop (a key
component of γ-secretase complex) was unaffected
(Fig. 6e, h), the activity of γ-secretase was induced by
Fig. 4 Nogo-A and NgR localization in APP/PS1 mice brain. a Mice brain sections were processed for anti-Aβ (6E10) and anti-Nogo-A immunohistology
as indicated. Bar = 50 μM. b Mice brain sections were processed for anti-Aβ (6E10) and anti-Iba1 immunohistology as indicated. Bar = 50 μM. c Mice
brain sections were processed for anti-NgR and anti-Iba1 immunohistology as indicated. Bar = 50 μM
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the CM (Fig. 6i). Furthermore, NgR siRNA treatment
significantly attenuated the effects of Nogo-P4 on the
expression and activity of secretase compared with con-
trol siRNA. Results above suggested that the CM from
BV-2 microglia activated by Nogo/NgR is responsible for
the expression and amyloidogenic processing of APP in
neurons.
Tau phosphorylation level in primary neurons were
promoted by the CM from Nogo/NgR-activated BV-2
microglia
Furthermore, we investigated whether the phosphory-
lated levels of tau were influenced by the CM from BV-2
microglia activated by Nogo/NgR. Results of western
blot showed that there was no significant change in the
expression of tau-1, the non-phosphorylated tau, among
different conditions (Fig. 7a, b). After neurons were
stimulated by the CM from Nogo-P4-activated BV-2
microglia for 24 h, the p-tau level at Ser202/Thr205 de-
tected by AT8 in neurons was increased and the increase
could be blocked by pretreatment with NgR siRNA
(Fig. 7c, d). However, the CM did not alter the phos-
phorylated level of tau at Ser396 detected by PHF-13
(Fig. 7c, e). Moreover, after neurons were stimulated by
the CM, the phosphorylated level of GSK-3β was en-
hanced, and the phosphorylation was attenuated by pre-
treatment with NgR siRNA (Fig. 7f, g). Therefore, the
CM from the BV-2 microglia activated by Nogo/NgR
contributes to the phosphorylation of tau and GSK-3β in
primary cultured neurons.
Fig. 5 CM from BV-2 microglia activated by Nogo/NgR pathway increased the production and aggregation of Aβ. After exposing for CM of BV-2
microglia for 24 h, ELISA was performed to detect the production of Aβ40 (a) and Aβ42 (b) and the secretion of Aβ40 (c) and Aβ42 (d). Values
were reported as mean ± SD. The aggregation of Aβ (e) and the depolymerization of fibrillar Aβ (f) were determined using ThT binding assay.
Values were reported as mean ± SD, as a percentage of values determined in PBS group (control, 100 %). *p < 0.05, **p < 0.01, ***p < 0.01, n = 3
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The expression of proinflammatory mediators was
increased and anti-inflammatory mediators were
decreased in the CM of BV-2 microglia activated by
Nogo/NgR
Our previous research found that Nogo-P4 elevated the
expression of proinflammatory mediators in microglia in
vitro, such as IL-1β, TNF-α, prostaglandin E2 (PGE2),
nitric oxide (NO) [19]. In the present study we examined
whether proinflammatory cytokines from microglia acti-
vated by the Nogo/NgR signaling pathway is involved in
AD pathological features. As shown in Fig. 8, the levels
of transcripts of M1-inflammatory gene markers (iNOS,
IL-1β, TNF-α, IL-6, COX-2) from Nogo-P4 activated
BV-2 microglia were higher than the control BV-2
microglia but the levels of the transcripts of M2-
inflammatory gene markers (Arg1, Fizz1, Ym1, IL-4,
cd206, IL-10) were lower. Moreover, NgR siRNA treat-
ment significantly reversed the effects of Nogo-P4 on
the expression of M1 and M2 inflammatory genes com-
pared with control siRNA. These results implied that the
Nogo/NgR pathway could induce the proinflammatory
environment in BV-2 microglia, and the blockage of the
Nogo/NgR pathway might change the neuroinflamma-
tory environment from proinflammation to anti-
inflammation.
Furthermore, we investigated the neuroinflammation
after the inhibition of the Nogo/NgR signaling pathway
in APP/PS1 mice. The expression of inflammatory medi-
ators in APP/PS1 mice was determined using western
blot, ELISA and RT-PCR. Results showed that NEP1-40
Fig. 6 The CM derived from Nogo/NgR-activated BV-2 microglia increased the expression and amyloidogenic processing of APP. Neurons were
exposed for CM of BV-2 microglia at different treatments for 24 h. The expression of APP (a, b), BACE1 (a, c), ADAM10 (e, f), and PS1 loop (e, h)
was determined using western blot. Values were reported as mean ± SD, as a percentage of values determined in the PBS group (control, 100 %).
FRET assay was performed to detect the activity of β-secretase (d), α-secretase (g), and γ-secretase (i). Values were reported as mean ± SD, as a
percentage of values determined in the PBS group (control, 100 %). *p < 0.05, **p < 0.01, ***p < 0.01, n = 3
Fang et al. Journal of Neuroinflammation  (2016) 13:56 Page 11 of 17
administration decreased the levels of proinflammatory
mediators including COX-2 (Fig. 9a–c), iNOS (Fig. 9d–
f ), IL-1β (Fig. 9g, h), TNF-α (Fig. 9i), and IL-6 (Fig. 9j),
but no change in the transcription of the CCL2 was
found (Fig. 9k). NEP1-40 infusion also promoted the ex-
pression of anti-inflammatory cytokines including Arg1
(Fig. 9l), Fizz1 (Fig. 9m), Ym1 (Fig. 9n), cd206 (Fig. 9o),
IL-10 (Fig. 9p), and IL-4 (Fig. 5q–r) in the brain com-
pared with the vehicle group. These results are consist-
ent with those in vitro and indicate that the Nogo/NgR
signaling pathway induced neuroinflammation in APP/
PS1 transgenic mice, which might contribute to the pro-
duction of the pathological features in AD.
Discussion
In this study, the evidence of an important regulation
of the formation of Aβ plaques and hyperphosphory-
lation of tau by neuroinflammation triggered by
Nogo/NgR pathway in vivo and in vitro is presented.
From the results presented above, two points are par-
ticularly noteworthy. Firstly, the results from the
present study in vivo confirmed that Nogo/NgR sig-
naling pathway participated in the formation of
pathological features in AD. Inhibition of the Nogo/
NgR signaling pathway significantly reduced the de-
position of Aβ and phosphorylation of tau in APP/
PS1 mice. NEP1-40, a competitive antagonist peptide
Fig. 7 Tau phosphorylation in primary neurons were promoted by the CM from Nogo/NgR-activated BV-2 microglia. Neurons were exposed to
the CM of BV-2 microglia at different stimulations for 24 h. The expression of tau (a, b) was determined using western blot. Values were reported
as mean ± SD, as a percentage of values determined in the PBS group (control, 100 %). Effects of CM from Nogo/NgR pathway activated BV-2
microglia on tau phosphorylation (c–e) and GSK-3β activation (f, g) in primary neurons were measured using western blot. Values were reported
as mean ± SD. *p < 0.05, **p < 0.01, n = 3
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of the Nogo/NgR pathway, is previously shown to
promote axon regeneration and improve outcome
after spinal cord injury and stroke in vivo [33, 39, 40].
Thus, NEP1-40 could effectively inhibit the Nogo/
NgR pathway and is safe to use in animal models. Re-
cent studies indicate that both Nogo and NgR con-
tributed to the pathology of AD. For example, deleting
Nogo improves cognitive function of APP transgenic
mice [8] and intracerebroventricular administration of
soluble NgR reduces brain Aβ plaque load [7, 12].
Additionally, Nogo receptor regulated Aβ production
via interaction with APP and BACE1 and NgR2 abla-
tion in AD mice resulted in the decrease of amyloid
deposition [41]. Our results are consistent with these
published data, showing that the blockage of Nogo/
NgR pathway significantly attenuated amyloidogenic
processing of APP and the activity of GSK3β in AD
mice, which reduced Aβ deposition and phosphory-
lated levels of tau, respectively.
Secondly, we also verified that neuroinflammatory
environment generated from the Nogo/NgR-activated
BV-2 microglia induced the production of Aβ and phos-
phorylation of tau, which at least partially accounted for
NEP1-40 function in vivo. As Nogo receptor is
expressed in both neurons and microglia, we dissect
what the cellular component that NEP1-40 acts by iso-
lating microglia from neurons in vitro. Using BV-2
microglia in culture, we interfered with the expression of
NgR by siRNA in the presence and absence of Nogo
peptide to generate the conditioned medium with differ-
ent conditions with or without Nogo/NgR activations.
Using the CM from different microglia, we addressed
the question of whether the CM from Nogo/NgR-acti-
vated BV-2 microglia can promote amyloidogenesis and
Fig. 8 Increasing of M1 inflammatory gene and decreasing of M2 inflammatory gene in Nogo/NgR-activated BV-2 microglia. Before added to the
protein-coated wells, BV-2 microglia was transfected with control or NgR siRNA to suppress the expression of NgR. The cells were then stimulated
by exposed to PBS or Nogo-P4 for 6 h. The levels of M1 (a–f) and M2 (g–l) inflammatory gene transcripts in BV-2 microglia were examined by
quantitative RT-PCR. a iNOS. b IL-1β. c TNF-α. d IL-6. e COX-2. f CCL2. g Arg1. h Fizz1. i Ym1. j IL-4. k cd206. l IL-10. Values were reported as mean
± SD, as a percentage of values determined in PBS group (control, 100 %). *p < 0.05, **p < 0.01, ***p < 0.01, n = 4
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tau hyperphosphorylation in neuronal cultures. Our data
clearly demonstrated that the CM from Nogo/NgR-acti-
vated BV-2 microglia promoted Aβ production and tau
hyperphosphorylation, the main pathological hallmarks
of AD. These changes activated by the CM could be
blocked by NgR siRNA treatment of BV-2 microglia. We
confirmed that high levels of proinflammatory cytokines
and gene transcripts but lower levels of anti-
inflammatory cytokines and gene transcripts are present
in the CM and lysates from Nogo/NgR-activated BV-2
microglia. These cytokine changes can be reversed by
the treatment of microglia with siRNA of NgR. Our data
indicated that the changes of the cytokine profiles in the
BV-2 microglia were due to the regulation of the Nogo/
Fig. 9 Inhibition of the Nogo/NgR pathway improved neuroinflammatory environment in APP/PS1 mice. Homogenates from brain tissue of 8-month-
old APP/PS1 transgenic mice were subjected to western blot to measure the expression of COX-2 and iNOS. a, b COX-2. d, e iNOS. Values were
reported as mean ± SD, as a percentage of values determined in the vehicle group (control, 100 %). The brain of APP/PS1 mice was homogenized, and
the proportions of IL-1β (g) and IL-4 (q) were determined using ELISA. Values were reported as mean ± SD. Inflammatory gene transcripts in the brain
from 8-month-old APP/PS1 mice were measured by quantitative RT-PCR. c COX-2. f iNOS. h IL-1β. i TNF-α. j IL-6. k CCL2. l Arg1. m Fizz1. n Ym1.
o cd206. p IL-10. r IL-4. Values were reported as mean ± SD, as a percentage of values determined in the vehicle group (control, 100 %). *p < 0.05;
**p < 0.01; ***p < 0.001, when compared with the vehicle group, n = 3–6
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NgR pathway in these microglia. Our data also indicated
that primary neurons can respond to the proinflamma-
tory factors present in CM for Aβ production and tau-
phosphorylation. However, our data could not eliminate
the possibility that NEP1-40 could directly act on
neurons to modulate Aβ production and tau
phosphorylation.
Microglia, the resident immune cells in the brain, play
core roles in neuroinflammation. The activation of micro-
glia exerts both toxic and protective effects on AD patho-
genesis. Many research have proven that a lot of
proinflammatory mediators enhance the expression and
the amyloidogenic processing of APP to increase the pro-
duction of Aβ [42]. For example, LPS could induce the re-
lease of proinflammatory cytokines including IL-1β, TNF-α,
and so on and further exacerbate Aβ and tau pathology
[43–45]. IL-1β and TNF-α contribute to the production of
APP and its processing into Aβ in vitro and in vivo [46, 47].
Moreover, IL-4 enhances M2 phenotype in vivo and reveals
a trend toward a decreased trend in Aβ deposition [48].
Furthermore, accumulating evidence links the microglia-
driven neuroinflammatory responses to NFT formation and
tau pathology [49]. For instance, IL-1β has been shown to
increase tau phosphorylation increasing the activity of
GSK-3β and MAPK [50, 51]. This evidence demonstrates
that neuroinflammation is involved in AD pathogenesis.
Our results showed that neuroinflammation induced by
Nogo/NgR pathway activation also affected AD pathogen-
esis. The inhibition of the Nogo/NgR pathway improved
the neuroinflammatory environment in APP/PS1 mice. The
neuroinflammatory environment from Nogo/NgR pathway
activation increased Aβ production and tau phosphoryl-
ation in neurons. Furthermore, Aβ aggregation termed β-
amyloid fibrils is associated with AD [52, 53], and Aβ1–42
has been shown to aggregate into amyloid fibrils more
readily than Aβ1–40 [54]. When treated with neuroinflam-
matory medium from Nogo/NgR pathway-activated BV-2
microglia, the aggregation of Aβ1–42 was enhanced and
depolymerization of Aβ1–42 was decreased. After activation,
microglia secrete inflammatory mediators and reactive oxy-
gen species, which can aggravate the aggregation of Aβ in
AD [55]. For example, IL-1β induces the expression of APP
and increases intracellular aggregation of Aβ in human
myotubes [56]. Hence, inflammatory mediators in CM from
Nogo/NgR pathway-activated BV-2 microglia might aggra-
vate the aggregation of Aβ and the mechanism need to fur-
ther study. This data suggested that neuroinflammation
from Nogo/NgR pathway activation in microglia partici-
pated in AD pathogenesis via modulating the balance be-
tween proinflammatory and anti-inflammatory mediators.
The expression of NgR is increased in patients with
AD and aged rats with deficits of spatial cognition
[9, 10]. Moreover, our previous research found that
with aging, the expression of NgR on microglia was
significantly increased [57], and Nogo bound with
NgR on microglia increased the expression of proin-
flammatory cytokines [19]. In this study, we found
that neuroinflammation induced by Nogo/NgR path-
way in microglia could enhance the formation of Aβ
plaques and hyperphosphorylation of tau. Thus, as
aging, the increased expression of NgR might pro-
mote microglia become more proinflammatory, result-
ing in increased Aβ accumulation and occurrence and
deterioration of AD. Furthermore, apart from Aβ and
tau pathophysiology in AD, Nogo/NgR pathway may
play roles in synaptic damage. Proinflammatory cyto-
kines, reactive oxygen species, and neurotoxic prod-
ucts involve in synaptic damage in AD [58]. Thus,
Nogo/NgR pathway may contribute to synaptic loss in
AD directly and indirectly.
Despite several studies that imply the relationship be-
tween the Nogo, NgR, and AD, only a few detailed mecha-
nisms have been provided to date. Two points are
particularly novel contributions to this field in our study.
Firstly, the Nogo/NgR signaling pathway participated in
the formation of pathological features including depos-
ition of Aβ and phosphorylation of tau in AD. Secondly,
neuroinflammatory environment generated from the
Nogo/NgR-activated microglia induced the production of
Aβ and phosphorylation of tau, which at least partially
accounted for NEP1-40 function in vivo. These results
imply a better understanding of the role of Nogo/NgR sig-
naling pathway in AD and offer a new strategy to treat
AD. Small-molecular drugs and natural drugs could be in-
vestigated to target Nogo/NgR pathway, and these drugs
may be new therapeutic use in AD.
Although our findings in these studies are important
and reveal a critical mechanism of Nogo/NgR-activated
microglia underlying inflammation-induced pathogenesis
of AD, there are also limitations. It is still not known
what exact factor in the CM plays a key role in the AD
pathogenesis is also unknown. Whether the Nogo/NgR
pathway on microglia has any effect on Aβ clearance by
microglia remains unclear, and our team is working hard
in this field. Future studies should focus to address these
critical questions.
Conclusions
In summary, the neuroinflammation regulated by Nogo/
NgR pathway was involved in the formation of Aβ pla-
ques and tau hyperphosphorylation in AD. The suppres-
sion of the Nogo/NgR pathway by NEP1-40 attenuated
the deposition of Aβ plaque, improved tau pathology,
and inhibited detrimental neuroinflammation in AD
mice. Moreover, neuroinflammatory CM from Nogo/
NgR-activated BV-2 microglia exacerbated the produc-
tion of Aβ and phosphorylation of tau in neurons. These
results suggest a better understanding of the role of
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neuroinflammation produced by Nogo/NgR-activated
microglia on the pathogenic mechanism of AD and offer
a new strategy to treat AD.
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suppress the expression of NgR. The cells were then exposed to PBS or
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centrifuged to discard cell debris. The release of Aβ40 (Figure A) and
Aβ42 (Figure B) in the conditioned medium was determined using ELISA.
Values were reported as mean ± SD. n = 3. (PDF 95 kb)
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